{"url_path":"/sec/eltp/10-k/2026/item-12","section_key":"item-12","section_title":"Item 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-031070-index.html","accession_number":"0001493152-26-031070","cik":"0001053369","ticker":"ELTP","issuer_name":"ELITE PHARMACEUTICALS INC /NV/","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-031070-index.html","primary_entity_key":"0001053369","primary_entity_name":"ELITE PHARMACEUTICALS INC /NV/"},"word_count":520,"has_tables":true,"body_markdown":"** ** \n\n**ITEM\n12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**\n\n** **\n\nThe\nfollowing table sets forth certain information, as of June 29, 2026 (except as otherwise indicated), regarding beneficial ownership of\nour Common Stock by (i) each person who is known by us to own beneficially more than 5% of each such class, (ii) each of our directors,\n(iii) each of our executive officers and (iv) all our directors and executive officers as a group. As of June 29, 2026 we had 1,077,096,442\nshares of Common Stock outstanding (exclusive of 0.1 million treasury shares). On any matter presented to the holders of our Common Stock\nfor their action or consideration at any meeting of our Shareholders, each share of Common Stock entitles the holder to one vote.\n\n \n\nAs\nused in the table below and elsewhere in this report, the term beneficial ownership with respect to a security consists of sole or shared\nvoting power, including the power to vote or direct the vote, and/or sole or shared investment power, including the power to dispose\nor direct the disposition, with respect to the security through any contract, arrangement, understanding, relationship, or otherwise,\nincluding a right to acquire such power(s) during the 60 days immediately following June 29, 2026. Except as otherwise indicated, the\nShareholders listed in the table have sole voting and investment powers with respect to the shares indicated.\n\n \n\nName and Address of Beneficial Owner of Common Stock \nCommon Stock  \n\n**Percent\n(%) of**\n\n**Voting\nSecurities**\n\n**Beneficially**\n\n**Owned**\n \n\nNasrat Hakim, President, Chief Executive Officer and Chairman of the Board of Directors* \n 300,581,058(1) \n 26.0%\n\nBarry Dash, Director* \n 3,235,555(2) \n **%\n\nJeffrey Whitnell, Director* \n 3,187,020(3) \n **%\n\nDavis Caskey, Director* \n 2,049,436(4) \n **%\n\nDouglas Plassche, Executive Vice President * \n 6,000,000(5) \n **%\n\nCarter Ward, Chief Financial Officer \n 6,990,445(6) \n **%\n\nAll Directors and Officers as a group \n 322,043,514(7) \n 27.9%\n\n \n\n*\nThe address is c/o Elite\nPharmaceuticals Inc., 165 Ludlow Avenue, Northvale, NJ 07647.\n\n \n\n**\nLess than 1%\n\n \n\n(1)Includes\n219,349,250 shares of Common Stock held by Mr. Hakim and 2,223,147 shares of Common Stock\nheld by Mr. Hakim’s spouse and 79,008,661 shares of Common Stock issuable upon cash\nexercise of the Series J Warrants with an exercise price of $0.1521 per share.\n\n \n\n(2)Includes\n3,235,555 shares of Common Stock held by Dr. Dash\n\n \n\n(3)Includes\n3,187,020 shares of Common Stock held by Mr. Whitnell\n\n \n\n(4)Includes\n2,049,436 shares of Common Stock held by Mr. Caskey.\n\n \n\n(5)Includes\n6,000,000 shares of Common Stock held by Mr. Plassche.\n\n \n\n(6)Includes\n4,990,445 shares of Common Stock held by Mr. Ward and shares of Common Stock issuable upon\ncash exercise of vested options to purchase 2,000,000 shares of Common Stock and excludes\n1,000,000 shares issuable upon exercise of options not vested or not exercisable within the\nnext 60 days.\n\n \n\n(7)Relates\nonly to current directors and officers. Includes 241,034,853 shares of Common Stock held,\n2,000,000 shares of Common Stock issuable upon cash exercise of vested options and 79,008,661\nshares of Common Stock issuable upon cash exercise of warrants at an exercise price of $0.1521\nper share of Common Stock, and excludes 1,000,000 shares issuable upon exercise of options\nnot vested or not exercisable within the next 60 days.\n\n \n\n64"}